Skip to Content

Humacyte Inc HUMA

Morningstar Rating
$5.24 −0.70 (11.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HUMA is trading at a 474% premium.
Price
$5.25
Fair Value
$69.37
Uncertainty
Extreme
1-Star Price
$262.13
5-Star Price
$5.35
Economic Moat
Lwf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HUMA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.94
Day Range
$5.175.79
52-Week Range
$1.969.97
Bid/Ask
$5.01 / $6.30
Market Cap
$624.00 Mil
Volume/Avg
4.5 Mil / 2.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
185

Comparables

Valuation

Metric
HUMA
PTGX
EQRX
Price/Earnings (Normalized)
12.88
Price/Book Value
23.863.290.97
Price/Sales
5.99
Price/Cash Flow
9.85
Price/Earnings
HUMA
PTGX
EQRX

Financial Strength

Metric
HUMA
PTGX
EQRX
Quick Ratio
8.2015.6118.43
Current Ratio
8.3715.7218.78
Interest Coverage
−15.49
Quick Ratio
HUMA
PTGX
EQRX

Profitability

Metric
HUMA
PTGX
EQRX
Return on Assets (Normalized)
−60.89%51.28%−15.72%
Return on Equity (Normalized)
−219.00%56.32%−16.71%
Return on Invested Capital (Normalized)
−136.12%51.24%−21.31%
Return on Assets
HUMA
PTGX
EQRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QyfclvvqgPxnkq$637.8 Bil
Vertex Pharmaceuticals Inc
VRTX
QnjryflpkCfyxlz$121.6 Bil
Regeneron Pharmaceuticals Inc
REGN
XfrgbvjYrvtpc$115.1 Bil
Moderna Inc
MRNA
CdmqcnlHlxv$51.5 Bil
argenx SE ADR
ARGX
SmzkswtmpXjbmc$22.9 Bil
BioNTech SE ADR
BNTX
ZvmmflfgpKys$20.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
VyzzndtRyfjbdl$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
QlpxjffqXvgrz$16.1 Bil
United Therapeutics Corp
UTHR
ZtxlxncdsCxrj$13.7 Bil
Incyte Corp
INCY
GhgwkcpkwYchrwqy$12.3 Bil

Sponsor Center